Liver Cancer Therapeutics Market to Reach $7,382.1 Million by 2027; Increasing Proclivity towards Biosimilars to Amplify Growth

The global liver cancer therapeutics market size is expected to reach USD 7,382.1 million by 2027. The growing development of immunotherapy and targeted drug therapy to achieve faster prognosis will have an outstanding effect on the market during the forecast period, mentioned in a report, titled “Liver Cancer Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Therapy Type (Targeted Drug Therapy, Immunotherapy, and Chemotherapy), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2020-2027.” The market size stood at USD 1,730.9 million in 2019 and is expected to exhibit a CAGR of 20.2% between 2020 and 2027.

US FDA Approval for Zymeworks' Liver Cancer Antibody to Boost Growth

Zymeworks Inc, a publicly held biotechnology company based in Vancouver, British Columbia, announced that it has received approval from the U.S. Food and Drug Administration to treat its experimental antibody zanidatamab individual patients with a type of cancer that affects the liver and gallbladder. Zanidatamab is being developed using Vancouver, British Columbia-based Zymeworks' Azymetric platform to treat biliary tract cancer that expresses the HER2 gene in patients who previously received other therapies. Biliary tract cancer is mostly developed in bile ducts, connecting the liver to the small intestine. The cancer is also known as cholangiocarcinoma, including gallbladder cancer and bile duct cancer. This type of cancer accounts for about 3% of all cancers in adults. More than 210,000 individuals are affected by this group of cancers worldwide each year. Moreover, Zymeworks initiated a global phase 2b study of zanidatamab to back accelerated approval of the therapy and plans to submit a biologics license application by 2022. In addition, Zanidatamab received two U.S. fast-track designations, one as a standalone therapy for biliary tract cancer and one in combination with chemotherapy for gastroesophageal adenocarcinoma.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/liver-cancer-therapeutics-market-104657

Potential Drug Pipeline to Spur Lucrative Opportunities

The increasing research and development to offer advanced care for cancer patients will favor the market's growth. Innovative experiments by major pharmaceutical companies for combination therapy with new or existing drug molecules have led to numerous pipeline candidates for liver cancer treatment. Moreover, government support and funding from international healthcare organizations will contribute positively to the market growth. The growing preference for biosimilars will consequently incite the development of the market in the forthcoming years. However, strict regulations associated with clinical studies by regulatory bodies can retard the expansion of the market.

Focus on Strong Sales Network by Companies to Consolidate Business

The market is dominated by major pharma companies owing to their strong presence in the market. The prominent companies are focused on liver cancer therapeutics to strengthen their position in the market. Bayer AG and Eisai Inc. hold the maximum share in the market. The dominance of players is attributable to strong sales of oncology drugs coupled with strategic investments and collaborations to proliferate product portfolio. Furthermore, the emergence of new players and product approvals will positively affect the market during the forecast period.

The Report Lists the key Players in the Liver Cancer Therapeutics Market:

• Bayer HealthCare Pharmaceuticals Inc. (Leverkusen, Germany)


• Bristol-Myers & Squibb Company (New York, U.S)


• Pfizer Inc. (New York, U.S)


• Exelixis, Inc. (California, U.S)


• Merck Sharp & Dohme Corp. (New jersey, U.S)


• Eisai Inc. (Tokyo, Japan)


• Eli Lilly and Company (Indiana, U.S)


• F. Hoffmann-La Roche Ltd (Basel, Switzerland)


• Other Players

Further Report Findings:

• Regional Analysis: Asia Pacific is expected to hold the largest market share due to the growing number of clinical studies about liver cancer. The rising geriatric population will further encourage growth in the region.


• Leading Segment:  The hospital pharmacy segment is expected to hold the lion’s share in the global market due to increased patient visits and sales of prescription-based drugs to treat liver cancer, mainly hepatocellular carcinoma.

The Liver Cancer Therapeutics Market is Segmented into: